William Makis

William Makis and Fenbendazole: What Do Three Cancer Cases Actually Show?

A detailed comparison with the outcomes of established cancer treatments

Evidence reviewed: October 27, 2026

A remission can be real while its cause remains uncertain. The central question in these three cases is whether adding fenbendazole improved the outcome beyond what the patients' other treatments could have achieved. Historical clinical trials help assess that question, although they cannot reconstruct an individual patient's alternative future.

A three-patient report coauthored by William Makis described breast, prostate and melanoma responses during fenbendazole use. It was subsequently retracted. This review examines the reported outcomes against conventional-treatment benchmarks, treating the clinical narratives as unverified reports rather than independently audited records. [1] [2]

The Study and Its Retraction

Karger retracted the paper on January 21, 2026, citing a potential undeclared conflict of interest: the first author offered services related to the study's topic at submission. The editor found the response to the concern unsatisfactory. The notice does not allege fabricated patients or scans. Retraction and confounding are separate issues: even without the disclosure problem, an uncontrolled case series involving multiple treatments cannot establish which treatment caused a response. [2]

How to Make a Fair Historical Comparison

The appropriate comparison is with patients receiving similar conventional treatment without fenbendazole. Comparing these outcomes with untreated cancer would give the added drug credit for benefits that established therapy may already explain. Endocrine therapy and immunotherapy are active cancer treatments even when conventional chemotherapy is absent.

Progression-free survival measures time until progression or death. Overall survival measures time until death. Objective response includes partial and complete tumour shrinkage; it is not synonymous with cure. A median describes a population midpoint, not a deadline for an individual. Trial populations also differ in fitness, previous treatment and disease burden.

Case 1: Metastatic Breast Cancer

Reported clinical picture: An 83-year-old with ER/PR-positive, HER2-negative recurrence after approximately 12 years had liver, lung and bone disease, malignant ascites and biliary obstruction. Fulvestrant and spinal radiation accompanied fenbendazole. A negative metabolic scan was reported by April 2022, followed by prolonged remission. [1]

What made the prognosis unfavorable? Extensive symptomatic organ involvement raises concern for deterioration and organ complications without effective systemic treatment. This is a much more serious presentation than isolated bone metastases. However, a precise untreated survival cannot be assigned without performance status, organ-function measurements and a fuller clinical record.

What made a conventional response plausible? Hormone-receptor positivity provides a target for endocrine therapy. A long interval before recurrence suggests potentially endocrine-sensitive biology, although the interval since stopping previous endocrine therapy is important. Fulvestrant directly targets estrogen-receptor signaling; it is not merely a supportive intervention.

Historical fulvestrant benchmarkResultInterpretive limit
FALCON: objective response in measurable disease46.1%Includes partial responses; not a complete-remission rate.
FALCON: median response duration among responders20 monthsApplies to responders, not every treated patient.
FALCON: median progression-free survival16.6 months overallPopulation benchmark, not individual life expectancy.

These figures show that substantial and sometimes durable regression can occur with fulvestrant alone. FALCON enrolled patients without previous endocrine therapy, making it an imperfect match for a previously treated patient. [3] [4]

Visceral-disease subgroup analyses provide additional context: median progression-free survival with fulvestrant was approximately 13.8 months in FALCON, 9.8 months in FIRST and 4.7 months in CONFIRM. These studies involved different treatment histories and populations. Their figures should not be combined into a personalized prediction or interpreted as survival estimates. [5]

Expected course with conventional treatment: Improvement or stabilization over the next several months was a realistic possibility if the disease remained endocrine-sensitive. Eventual progression would be more typical than a prolonged complete remission. Local radiation can account for improvement at treated sites; explaining distant disease control requires consideration of systemic treatment.

Documentation problem: The narrative says all treatments stopped but later describes continued daily fenbendazole. The fulvestrant duration needs clarification. [1] A brief endocrine course followed by years of remission would be more unusual than continued control during ongoing therapy. The distinction requires medication records, not inference.

Interpretation: This is the most exceptional of the three responses relative to the reported disease burden. Endocrine treatment remains a plausible explanation. An exceptional response warrants investigation, but does not establish fenbendazole as its cause.

Case 2: Metastatic Prostate Cancer

Reported clinical picture: A 75-year-old with recurrent bone and nodal disease began relugolix plus apalutamide alongside fenbendazole. PSA remained below 0.05 ng/mL, with radiographic regression beyond two years while conventional treatment continued. [1]

The key classification is hormone sensitivity. Initiating androgen deprivation at metastatic recurrence suggests a hormone-sensitive setting, conditional on previous therapy and testosterone results. Castration-resistant disease would require a different comparison. Relugolix suppresses testosterone; apalutamide blocks androgen-receptor signaling. This is substantial systemic treatment.

TITAN benchmarkApalutamide plus androgen deprivation
Alive without radiographic progression at 24 months68.2%
PSA decline of at least 90% by six months68%
PSA at or below 0.2 ng/mL by six months61%

TITAN demonstrates that profound PSA responses and control beyond two years are common with this therapeutic strategy. Its PSA threshold is less stringent than 0.05 ng/mL, and it does not specifically establish results for the exact relugolix regimen described here. Those limitations prevent assigning this patient an exact probability, but do not erase the strong conventional explanation. [6] [7]

Expected course with conventional treatment: A major PSA fall during the first months, followed by imaging improvement or stability and potentially several years of control before resistance develops, would be an established pattern. Not every patient achieves this; the response is favorable without being an obvious outlier.

A very low PSA during continuing hormonal suppression demonstrates disease control, not necessarily eradication. More precise matching would require pretreatment PSA, Gleason/ISUP grade, testosterone, prior hormonal exposure and an adequately documented metastatic burden.

Interpretation: This case offers the weakest basis for attributing additional benefit to fenbendazole. The observed course is readily compatible with a successful response to androgen deprivation plus apalutamide.

Case 3: Metastatic Melanoma

Reported clinical picture: BRAF-mutated melanoma recurred after prior adjuvant targeted therapy. Fenbendazole and two nivolumab doses preceded reported clearance, sustained for approximately 11 months. Surgery addressed a separate urothelial malignancy. [1]

Why older prognosis figures can mislead: Historical outcomes before checkpoint inhibitors are a poor comparison for a patient receiving nivolumab. The relevant question is whether this outcome falls within the responses seen with modern immunotherapy.

CheckMate 067: nivolumab aloneThree-year analysis
Objective response44%
Complete response16%
Progression-free at three years32%
Median overall survival37.6 months

These trial outcomes establish that complete and durable responses are a recognized effect of nivolumab. They describe a repeated-dose treatment strategy, not the probability of remission after exactly two doses. The trial population is also not an exact match for a patient previously given adjuvant targeted therapy. [8]

Expected course with conventional treatment: A nonresponder might progress early, whereas a responder could experience marked regression and durable control. This split makes a single median particularly uninformative for predicting an individual course.

Limited dosing does not rule out a substantial immune effect. A published melanoma case describes a durable response after radiotherapy followed by a single nivolumab dose. That different treatment setting establishes possibility, not a frequency estimate for this patient. It should not be used to imply that brief treatment is generally sufficient. [9]

The chronology is decisive. Infusion dates must be aligned with every tumour-DNA measurement and scan. A decline demonstrated before the first nivolumab dose would change interpretation of that early decline, but would still not prove fenbendazole causation. A decline after nivolumab would make attributing it to fenbendazole especially difficult. LDH, performance status, brain imaging and measured tumour burden are also needed for a closer prognostic comparison.

Interpretation: Rapid clearance after limited exposure is notable, but nivolumab remains a strong competing explanation. Eleven months of remission is compatible with an immunotherapy response; it does not establish an added fenbendazole effect.

What the Three Cases Establish—and What Remains Unknown

CaseAssessment against conventional-treatment data
Breast cancerExceptional response; treatment duration and original records need clarification.
Prostate cancerFavorable course within the established range for androgen-directed treatment.
MelanomaCompatible with a strong immunotherapy response; exact timing is essential.

The correct conclusion is not that conventional treatment has definitively explained every observation. It is that credible conventional explanations remain, and the case series cannot isolate an additional fenbendazole effect. Nor can it prove that the drug contributed nothing.

Selecting three favorable outcomes supplies no denominator. We need to know how many people started treatment, how many progressed or died, who stopped because of toxicity and who disappeared from follow-up. Multiplying trial response percentages to calculate the supposed improbability of these selected cases would be invalid: the patients were not randomly sampled and the response definitions and treatments differ.

A stronger investigation would obtain complete medication records, baseline and serial scans, independent response review and prespecified outcomes, followed by appropriately designed comparative research. Computational predictions or overlapping mechanisms cannot substitute for that evidence. Clinical synergy or antagonism with these combinations remains unresolved.

Research Interest and Safety

Fenbendazole has produced positive cell and mouse-xenograft findings, but another study found no inhibition of EMT6 tumour growth in mice and additive, rather than synergistic, cell-culture effects with docetaxel. The evidence is model-dependent. [10] [11] Human safety also cannot be assumed from veterinary use: serious liver injury associated with self-administration has been reported. [12]

Makis's Legal Situation: A Brief Summary

Makis was declared a vexatious litigant in 2018; parts of the order were set aside in 2020, but restrictions remained, as confirmed by the Alberta Court of Appeal in January 2026. [13] CPSA states that he has not held an active Alberta medical licence since February 2019. [15]

On March 4, 2026, the Alberta Court of King's Bench found him in civil contempt for breaching an August 2025 injunction restricting health services and protected medical titles, and issued a permanent injunction. Makis disputed the alleged breach; the court rejected his position. The judgment explicitly distinguishes unauthorized medical practice from the scientific question of ivermectin's efficacy. These findings concern professional authorization and compliance, not proof for or against fenbendazole. [14]

A More Defensible Conclusion

The three cases deserve different interpretations. The breast response is the most unusual, the prostate response is well aligned with established therapy, and the melanoma response remains compatible with checkpoint inhibition. None demonstrates that fenbendazole changed the expected course. Interest in repurposed drugs is reasonable, but confidence in a treatment should depend on reproducible benefit and adequately assessed harm.

This article evaluates evidence; it is not a treatment protocol. Decisions about medicines and supplements belong in discussion with a licensed oncology team.

References

  1. Retracted case series: Makis, Baghli and Martinez (2025)
  2. Publisher's retraction notice, January 21, 2026
  3. FALCON: fulvestrant versus anastrozole
  4. Fulvestrant prescribing information: response and response-duration data
  5. Fulvestrant outcomes by visceral involvement: FALCON, FIRST and CONFIRM
  6. TITAN: apalutamide for metastatic castration-sensitive prostate cancer
  7. TITAN: depth and timing of PSA response
  8. CheckMate 067: three-year outcomes in advanced melanoma
  9. Melanoma response after radiotherapy and a single nivolumab dose: case report
  10. Fenbendazole: positive cell and xenograft experiments (2018)
  11. Fenbendazole: negative EMT6 tumour findings and additive cell-culture effects (2013)
  12. Severe liver injury associated with fenbendazole self-administration (2024)
  13. Alberta Court of Appeal: 2026 ABCA 17
  14. Alberta Court of King's Bench: 2026 ABKB 159
  15. CPSA statement on William (Viliam) Makis, updated September 2026
  16. OneDayMD protocol article: secondary presentation of claims, not independent efficacy evidence

Method note: Patient details are taken from the published case narrative; original clinical records and supplementary patient files were not independently audited. Trial comparisons are contextual and cannot establish individual causation. The retracted paper is cited to identify the claims under review, not to endorse its conclusions.

No comments:

Post a Comment